| Name | Title | Contact Details |
|---|---|---|
Katy Ramsey |
VP - Total Rewards & Talent | Profile |
Mike Weinstein |
Executive Vice President and Chief Financial Officer | Profile |
Thomas Parker |
Senior VP & Chief Financial Officer | Profile |
Castle Creek Biosciences, Inc. is a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options. The company`s proprietary autologous fibroblast platform potentially allows for the development of personalized, targeted and redosable cell-based gene therapy product candidates for monogenic and chronic disorders. The company`s most advanced product candidate, dabocemagene autoficel (D-Fi), is currently being evaluated in a Phase 3 clinical trial for the localized treatment of chronic wounds due to recessive dystrophic epidermolysis bullosa (RDEB). The company is also currently evaluating FCX-013 in a Phase 1/2 clinical trial for the treatment of moderate to severe localized scleroderma. In addition, Castle Creek Biosciences is pursuing discovery and potential development of early-stage novel product candidates with the goal of expanding its robust pipeline into other rare diseases and broader indications where there are significant unmet needs. The company operates an in-house, commercial-scale manufacturing facility in Exton, Pennsylvania that benefits from the validated systems and processes previously implemented at the site for manufacture of an FDA-approved cell therapy product. Castle Creek Biosciences, Inc. is a portfolio company of Paragon Biosciences, LLC.
Olive View Medical Center is a Sylmar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arzeda The Protein Design Company is a synthetic biology company.
Kai Pharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Personalized regenerative medicines at scale.